文献速递消化道肿瘤与早癌消化内镜

综述:结直肠癌全程中的社会经济与种族或民族不平等——从差异到行动

Review Article: Socioeconomic and Racial or Ethnic Inequalities Across the Colorectal Cancer Continuum: From Disparities to Action.
PubMed 文献 · Aliment Pharmacol Ther · 2026-10-14

本文为叙述性综述,检索2000年1月至2026年3月发表的成人研究,评估结直肠癌在发病、筛查诊断、治疗、监测和生存各环节的社会经济与种族或民族不平等,并评价旨在缩小不平等的干预措施。结果显示弱势人群筛查参与更低、诊断更晚、治疗更不及时且生存更差,干预证据在筛查以外明显不足。

要点

  • 社会经济弱势与部分少数种族或民族人群结直肠癌发病率更高、筛查参与更低、诊断更晚、生存更差
  • 美国黑人患者五年生存率60.6%,白人患者66.7%,数十年间差距改善甚微
  • 邮寄粪便检测和患者导航可提高弱势人群筛查参与,但治疗、监测和生存期干预证据稀缺

核心结论

  • 改善结直肠癌整体预防与诊疗不能假定会缩小不平等,证据缺口已从记录差异转向证明如何缩小差异,尤其在筛查以外环节。
  • 应将公平性作为结直肠癌研究、实施、医疗质量评估和临床指南的明确结局指标。

研究设计与样本

  • 叙述性综述,检索MEDLINE、EMBASE、PubMed和ISI Web of Knowledge,纳入2000年1月至2026年3月发表的英文成人研究,采用饱和法。
  • 聚焦结直肠癌发病、筛查与诊断、治疗、监测和生存中的社会经济或种族与民族差异及相关干预。

主要发现

  • 社会经济弱势和部分种族或民族少数群体与高收入国家内更高的结直肠癌发病率、更低的筛查参与、更晚的诊断、更不及时或欠符合指南的治疗、更差的监测和更差的生存相关。
  • 美国黑人患者五年生存率为60.6%,白人患者为66.7%,该差距数十年间改善甚微。
  • 连续各阶段的不平等可能造成累积性劣势,干预证据在整个诊疗连续体上明显不均衡。

关键数值与推荐

  • 美国黑人患者结直肠癌五年生存率60.6%,白人患者66.7%。
  • 邮寄粪便检测外展和患者导航可提高服务不足人群的筛查参与。
  • 针对治疗、监测及更广泛生存期不平等干预的证据稀疏。

临床怎么用

  • 消化内科应关注弱势人群的筛查外展(如邮寄粪便检测)与患者导航,并在诊疗各环节警惕累积性劣势。
  • 将公平性指标纳入结直肠癌诊疗质量评估与随访监测,而不仅满足于总体结局改善。

局限性

  • 为叙述性综述,采用饱和法检索,未报告系统评价式的定量合并或偏倚评估。
  • 干预证据在筛查以外的治疗、监测和生存期环节明显不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Socioeconomic and racial or ethnic inequalities affect colorectal cancer (CRC) across the care continuum. Although increasingly documented, whether current interventions effectively reduce these inequalities remains uncertain. AIMS: To review socioeconomic and racial or ethnic inequalities in CRC incidence, screening and diagnosis, treatment, surveillance and survival and assess interventions designed to reduce them. METHODS: We conducted a narrative review of adult studies published in English between January 2000 and March 2026. MEDLINE, EMBASE, PubMed, and ISI Web of Knowledge were searched for studies addressing socioeconomic or racial and ethnic disparities in CRC, using a saturation approach. RESULTS: Socioeconomic disadvantage and belonging to some racial or ethnic minority groups were associated with higher CRC incidence within high-income countries, lower screening participation, later diagnosis, less timely or guideline-concordant treatment, poorer surveillance and worse survival. In the USA, five-year survival was 60.6% among Black patients versus 66.7% among White patients, with little improvement in this gap over several decades. Inequalities at successive stages may contribute to cumulative disadvantage. Intervention evidence was markedly uneven across the continuum. Mailed stool-test outreach and patient navigation increased screening among underserved populations, whereas evidence for interventions specifically reducing inequalities in treatment, surveillance, and broader survivorship was sparse. CONCLUSIONS: Improving overall CRC prevention and care cannot be assumed to reduce inequalities. The major evidence gap has shifted from documenting disparities towards demonstrating how to reduce them, particularly beyond screening. Equity should become an explicit outcome of CRC research, implementation, healthcare quality assessment and clinical guidelines.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bardou M, Martel M, Barkun AN, et al. Review Article: Socioeconomic and Racial or Ethnic Inequalities Across the Colorectal Cancer Continuum: From Disparities to Action. Aliment Pharmacol Ther. 2026. PMID: 42875946. doi:10.1111/apt.71021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。